Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Archivos Espanoles De Urologia|December 3, 2020
[Recurrence and progression after BCG.]Guillermo Lendínez-Cano, Inés Rivero-Belenchón, Rafael Antonio Medina-López
World Journal of Urology|April 27, 2024
Patient's self-reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposalGuillermo Lendínez-Cano, Ángel Vilches-Arenas, Belen Congregado-Ruíz, et al.
Biomedicines|May 16, 2023
Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen TherapyBelén Congregado Ruiz, Inés Rivero Belenchón, Guillermo Lendínez Cano, et al.
Urologia Internationalis|September 5, 2024
Description of Baseline Quality of Life in Patients Diagnosed with Metastatic Renal Cell CarcinomaGuillermo Lendínez-Cano, Carmen Belén Congregado Ruíz, Miguel Ángel Gómez Luque, et al.
The Canadian Journal of Urology|May 7, 2025
Differences at diagnosis between long-term survivors and not long-term survivors in metastatic renal cell carcinoma initially treated with TKIMiguel Ángel Gómez-Luque, Guillermo Lendínez-Cano, Carmen Belén Congregado-Ruiz, et al.
Urologia Internationalis|January 9, 2020
Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature ReviewIgnacio Osmán-García, C Belen Congregado-Ruiz, Guillermo Lendínez-Cano, et al.
Archivos Espanoles De Urologia|July 8, 2020
[Analysis of the quality of the information on the erectile dysfunction in YouTube.]Javier Mazuecos Quirós, José Pablo Pedraza Sánchez, José María Lozano Blasco, et al.
Diagnostics (Basel, Switzerland)|July 15, 2026
Multicenter Validation of a Risk Classification Cluster for Unfavorable Pathology in Prostatectomy Specimens of Patients with an Active Surveillance Expanded Inclusion CriteriaMaria Graus Romero, Cristobal Cobo Díaz, Guillermo Lendínez Cano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2025
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group TrialXavier Garcia-Del-Muro, Begoña P Valderrama, Ana Medina-Colmenero, et al.
Pageof 1